Ovid Therapeutics (OVID) Cash from Investing Activities (2016 - 2026)

Ovid Therapeutics' Cash from Investing Activities history runs 11 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 16.62% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.0 million (down 224.04% YoY) and the FY2025 annual result came in at -$49.9 million, down 191.32% from the prior year.
• Cash from Investing Activities was $5.9 million for Q1 2026 at Ovid Therapeutics, up from -$72.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $30.2 million in Q1 2023 and bottomed at -$80.7 million in Q2 2022.
• A 5-year average of -$4.7 million and a median of $5.1 million in 2025 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 9246.58% — and 2023, when it jumped 2908.96%.
• Ovid Therapeutics' Cash from Investing Activities stood at -$4.2 million in 2022, then sank by 1063.59% to -$48.5 million in 2023, then soared by 143.89% to $21.3 million in 2024, then sank by 438.45% to -$72.1 million in 2025, then jumped by 108.26% to $5.9 million in 2026.
• Business Quant data shows OVID's Cash from Investing Activities at $5.9 million in Q1 2026, -$72.1 million in Q4 2025, and $5.1 million in Q3 2025.